ASTRAZENECA PLC
Form 6-K
November 01, 2016
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of November 2016
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F X Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes No X
If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82

#### AstraZeneca PLC

## INDEX TO EXHIBITS

1.

Dealing by Person Closely Associated dated 01st November 2016

#### 1 November 2016 15:30

Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities

Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation

On 31 October 2016, Mrs Susan Chipchase notified us that, on 27 October 2016, she purchased 100 AstraZeneca PLC Ordinary Shares of US\$0.25 each at a price of £48.08 per share.

Mrs Chipchase is a person closely associated with Graham Chipchase, a Non-Executive Director of AstraZeneca PLC. The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of the person discharging managerial responsibilities / person closely associated

a) Name Susan Chipchase

2 Reason for the notification

Person Closely Associated with a Person Discharging Managerial

a) Position/status

Responsibilities
(PDMR) in respect of
AstraZeneca PLC

b) Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name AstraZeneca PLC

b) LEI Not applicable

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)

each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument Identification code

Ordinary Shares of US\$0.25 each in

AstraZeneca PLC GB0009895292

Nature of the transaction Acquisition

> Price(s) Volume(s)

Price(s) and volume(s) c)

4807.95 100

pence

Aggregated information

Not applicable - single - Aggregated volume d)

transaction

- Price

Date of the transaction 27 October 2016

Place of the transaction London f)

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas -Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries

Neil Burrows	UK/Global	+44 203 749 5637	
Vanessa Rhodes	UK/Global	+44 203 749 5736	
Karen Birmingham	UK/Global	+44 203 749 5634	
Rob Skelding	UK/Global	+44 203 749 5821	
Jacob Lund	Sweden	+46 8 553 260 20	
Michele Meixell	US	+1 302 885 2677	
Investor Relations			
Thomas Kudsk Larsen		+44 203 749 5712	
Craig Marks	Finance, Fixed Income, M&A	+44 7881 615 764	
Henry Wheeler	Oncology	+44 203 749 5797	
Mitchell Chan	Oncology	+1 240 477 3771	

Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970

Nick Stone Respiratory +44 203 749 5716

Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711

US toll free +1 866 381 7277

Adrian Kemp Company Secretary, AstraZeneca PLC -ENDS-

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 November 2016 By: /s/ Adrian Kemp

Name: Adrian Kemp Title: Company Secretary